{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:50:45Z","timestamp":1791917445560,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jmii.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T12:04:29Z","timestamp":1743336269000},"page":"383-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recommendations and guidance for human papillomavirus (HPV) vaccination for adults in Taiwan"],"prefix":"10.1016","volume":"58","author":[{"given":"Kuan-Yin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Fan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Feng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chia","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ning","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-0815","authenticated-orcid":false,"given":"Wei-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Chiu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-2479","authenticated-orcid":false,"given":"Chien-Hsien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Chang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-2825","authenticated-orcid":false,"given":"Ping-Ing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee Siang","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-1919","authenticated-orcid":false,"given":"Ming-Han","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-2414","authenticated-orcid":false,"given":"Susan Shin-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2025.03.009_bib1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/jmv.21870","article-title":"Prevalence of human papillomavirus genotypes in northern Taiwanese women","volume":"82","author":"Tsao","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.jmii.2025.03.009_bib3","first-page":"637","article-title":"Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues","volume":"52","author":"Boda","year":"2018","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.jmii.2025.03.009_bib5","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMcp2108502","article-title":"Human papillomavirus vaccination","volume":"388","author":"Markowitz","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1016\/j.jmii.2025.03.009_bib6","doi-asserted-by":"crossref","first-page":"S849","DOI":"10.1093\/cid\/civ813","article-title":"Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines","volume":"61","author":"Park","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib7","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jmii.2025.03.009_bib8","series-title":"CERVARIX: Full Prescription Information (Package Insert)","year":"2024"},{"key":"10.1016\/j.jmii.2025.03.009_bib9","series-title":"GARDASIL: Full Prescription Information (Package Insert)","year":"2015"},{"key":"10.1016\/j.jmii.2025.03.009_bib10","series-title":"GARDASIL 9: Full Prescription Information (Package Insert)","year":"2024"},{"key":"10.1016\/j.jmii.2025.03.009_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2014-051813","article-title":"Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme","volume":"91","author":"Chow","year":"2015","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.jmii.2025.03.009_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S0950268815002198","article-title":"Prophylactic HPV vaccination: past, present, and future","volume":"144","author":"Castle","year":"2016","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jmii.2025.03.009_bib17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2021.03.025","article-title":"Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3","volume":"161","author":"Giannella","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib19","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jmii.2025.03.009_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2025.03.009_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jmii.2025.03.009_bib22","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"key":"10.1016\/j.jmii.2025.03.009_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jmii.2025.03.009_bib24","unstructured":"GRADEpro guideline development tool [software], McMaster University (developed by Evidence Prime, Inc.). Available at: http:\/\/gradepro.org. [Accessed 1 November 2024]."},{"key":"10.1016\/j.jmii.2025.03.009_bib25","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ygyno.2019.05.024","article-title":"Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women","volume":"154","author":"Aro","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib27","article-title":"Age-related changes in the fraction of cervical intraepithelial neoplasia grade 3 related to HPV genotypes included in the nonavalent vaccine","volume":"2019","author":"Giannella","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ijc.25685","article-title":"Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women","volume":"128","author":"Chen","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/v15102015","article-title":"Trend of HPV molecular epidemiology in the post-vaccine era: a 10-year study","volume":"15","author":"Lin","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jmii.2025.03.009_bib30","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ijc.22538","article-title":"Human papillomavirus genotype in cervical cancer: a population-based study","volume":"120","author":"Lai","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/591095","article-title":"Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men","volume":"198","author":"Giuliano","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib32","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/521192","article-title":"Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students","volume":"196","author":"Partridge","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(10)62342-2","article-title":"Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study","volume":"377","author":"Giuliano","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2025.03.009_bib34","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1086\/425907","article-title":"Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results","volume":"190","author":"Mu\u00f1oz","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ijc.33185","article-title":"A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale","volume":"148","author":"Clifford","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jama.2012.101","article-title":"Prevalence of oral HPV infection in the United States, 2009-2010","volume":"307","author":"Gillison","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2025.03.009_bib37","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/M17-1363","article-title":"Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014","volume":"167","author":"Sonawane","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/infdis\/jiu116","article-title":"High-risk oral human papillomavirus load in the US population, national health and nutrition examination survey 2009-2010","volume":"210","author":"Chaturvedi","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12885-023-10651-6","article-title":"Incidence trends of oral cavity, oropharyngeal, hypopharyngeal and laryngeal cancers among males in Taiwan, 1980-2019: a population-based cancer registry study","volume":"23","author":"Tsai","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ijc.29330","article-title":"Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009","volume":"137","author":"Hwang","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12885-022-09407-5","article-title":"Rising incidence of HPV positive oropharyngeal cancer in Taiwan between 1999 and 2014 where betel nut chewing is common","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2239085","article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review","volume":"19","author":"Ellingson","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2025.03.009_bib43","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2021.01.074","article-title":"Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: an open-label phase 3 study","volume":"39","author":"Joura","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib44","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.vaccine.2022.02.061","article-title":"Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: a phase 3 open-label study","volume":"40","author":"Lv","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djaa010","article-title":"Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Tsang","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmii.2025.03.009_bib47","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1016\/j.vaccine.2018.08.009","article-title":"Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up","volume":"37","author":"Wei","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib48","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2025.03.009_bib49","article-title":"Human papillomavirus vaccine impact and effectiveness in six high-risk populations: a systematic literature review","volume":"10","author":"Goodman","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jmii.2025.03.009_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12905-018-0707-9","article-title":"HPV vaccine in the treatment of usual type vulval and vaginal intraepithelial neoplasia: a systematic review","volume":"19","author":"Bryan","year":"2019","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.jmii.2025.03.009_bib51","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.vaccine.2023.08.047","article-title":"Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer","volume":"41","author":"Reuschenbach","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2078626","article-title":"Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years","volume":"18","author":"Maldonado","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2025.03.009_bib54","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.vaccine.2018.12.030","article-title":"Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up","volume":"37","author":"Chen","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib55","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1071\/SH17013","article-title":"Estimating the burden of genital warts in Taiwan","volume":"14","author":"Tsai","year":"2017","journal-title":"Sex Health"},{"key":"10.1016\/j.jmii.2025.03.009_bib58","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib59","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2022.02.042","article-title":"Long-term effectiveness of human papillomavirus vaccines among adult women: a real-world scenario","volume":"40","author":"Lee","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib60","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/OLQ.0000000000000742","article-title":"Early evidence of the effectiveness of the human papillomavirus vaccination program against anogenital warts in Manitoba, Canada: a Registry Cohort Study","volume":"45","author":"Willows","year":"2018","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib61","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S1473-3099(21)00071-2","article-title":"Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18","volume":"21","author":"Chow","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib62","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1016\/j.vaccine.2018.09.011","article-title":"Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions","volume":"36","author":"Dehlendorff","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib63","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","article-title":"Immunogenicity and safety of the 9-valent human papillomavirus vaccine in solid organ transplant recipients and adults infected with human immunodeficiency virus (HIV)","volume":"73","author":"Boey","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib64","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1016\/j.vaccine.2020.07.055","article-title":"Prophylactic HPV vaccination after conization: a systematic review and meta-analysis","volume":"38","author":"Jentschke","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib65","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00404-018-4926-y","article-title":"Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease","volume":"298","author":"Pieralli","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jmii.2025.03.009_bib66","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.vaccine.2019.01.069","article-title":"Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, Phase 3, placebo-controlled study","volume":"37","author":"Mikamo","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib68","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jmii.2025.03.009_bib69","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1016\/j.vaccine.2016.06.056","article-title":"A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib70","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Castellsagu\u00e9","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib71","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib73","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib74","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1016\/j.vaccine.2015.08.072","article-title":"Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study","volume":"33","author":"Giuliano","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jncimonographs\/lgae041","article-title":"Impact of single-dose HPV vaccination on HPV 16 and 18 prevalence in South African adolescent girls with and without HIV","volume":"2024","author":"Delany-Moretlwe","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jmii.2025.03.009_bib77","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jit657","article-title":"Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial","volume":"209","author":"Toft","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib78","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study","volume":"31","author":"Denny","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/v13020144","article-title":"Effectiveness of the quadrivalent HPV vaccine in preventing anal \u2265 HSILs in a Spanish population of HIV+ MSM aged > 26 years","volume":"13","author":"Hidalgo-Tenorio","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jmii.2025.03.009_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12981-017-0160-0","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)","volume":"14","author":"Hidalgo-Tenorio","year":"2017","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jmii.2025.03.009_bib81","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/cid\/ciy274","article-title":"A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298","volume":"67","author":"Wilkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib82","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/cid\/ciu238","article-title":"Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women","volume":"59","author":"Kojic","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib83","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1016\/j.vaccine.2016.08.016","article-title":"HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine","volume":"34","author":"Money","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib84","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/ajt.12329","article-title":"Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients","volume":"13","author":"Kumar","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jmii.2025.03.009_bib85","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamaoncol.2019.6722","article-title":"Immune response following quadrivalent human papillomavirus vaccination in women after hematopoietic allogeneic stem cell transplant: a nonrandomized clinical trial","volume":"6","author":"Stratton","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib86","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/MIB.0b013e318281341b","article-title":"Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease","volume":"19","author":"Jacobson","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib87","first-page":"29","volume":"vol. 11","author":"Soybilgic","year":"2013"},{"key":"10.1016\/j.jmii.2025.03.009_bib88","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jmii.2025.03.009_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2025.03.009_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv302","article-title":"Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection","volume":"108","author":"Beachler","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmii.2025.03.009_bib91","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.32791","article-title":"Effectiveness of the AS04-adjuvanted HPV-16\/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial","volume":"147","author":"Lehtinen","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmii.2025.03.009_bib92","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D'Souza","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib93","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/jamaoncol.2015.5504","article-title":"Associations of oral \u03b1-, \u03b2-, and \u03b3-human papillomavirus types with risk of incident head and neck cancer","volume":"2","author":"Agalliu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jop.13091","article-title":"The impact of HPV vaccination on the prevalence of oropharyngeal cancer (OPC) in a hospital-based population: a cross-sectional study of patient's registry","volume":"50","author":"Katz","year":"2021","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib95","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2017.75.0141","article-title":"Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States","volume":"36","author":"Chaturvedi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmii.2025.03.009_bib96","first-page":"Cd009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jmii.2025.03.009_bib97","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib98","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3736201","article-title":"Safety of human papillomavirus 9-valent vaccine: a meta-analysis of randomized trials","volume":"2017","author":"Costa","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jmii.2025.03.009_bib99","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jmv.27304","article-title":"The comparative safety of human papillomavirus vaccines: a Bayesian network meta-analysis","volume":"94","author":"Huang","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.jmii.2025.03.009_bib100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiy133","article-title":"Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries","volume":"218","author":"Garland","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib101","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4340","article-title":"Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes","volume":"4","author":"Kharbanda","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jmii.2025.03.009_bib102","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2022.11.009","article-title":"Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use","volume":"41","author":"Hansen","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib103","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/aje\/kwab022","article-title":"A Broad Safety Assessment of the 9-valent human papillomavirus vaccine","volume":"190","author":"Yih","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jmii.2025.03.009_bib104","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2023.11.010","article-title":"Adverse events from HPV vaccination in Taiwan","volume":"41","author":"Tsai","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib105","article-title":"Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study","volume":"372","author":"Yoon","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jmii.2025.03.009_bib106","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pvr.2018.02.002","article-title":"No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study","volume":"5","author":"Suzuki","year":"2018","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.jmii.2025.03.009_bib107","article-title":"Real-life safety profile of the 9-valent HPV vaccine based on data from the Puglia region of southern Italy","volume":"10","author":"Di Lorenzo","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jmii.2025.03.009_bib108","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2025.03.009_bib109","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study","volume":"12","author":"Romanowski","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2025.03.009_bib111","article-title":"Immunogenicity of alternative dosing schedules for HPV vaccines among adolescent girls and young women: a systematic review and meta-analysis","volume":"8","author":"Secor","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jmii.2025.03.009_bib112","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.vaccine.2019.12.017","article-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials","volume":"38","author":"Whitworth","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1152057","article-title":"Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials","volume":"11","author":"Kemin","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.jmii.2025.03.009_bib114","doi-asserted-by":"crossref","first-page":"e1485","DOI":"10.1016\/S2214-109X(22)00306-0","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial","volume":"10","author":"Baisley","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jmii.2025.03.009_bib115","doi-asserted-by":"crossref","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial","volume":"10","author":"Watson-Jones","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jmii.2025.03.009_bib116","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jmii.2025.03.009_bib117","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib118","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib119","article-title":"A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji","volume":"37","author":"Reyburn","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.jmii.2025.03.009_bib120","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciz239","article-title":"Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study","volume":"70","author":"Verdoodt","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.03.009_bib121","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2352-4642(18)30220-7","article-title":"Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study","volume":"2","author":"Silverberg","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jmii.2025.03.009_bib122","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2025.03.009_bib123","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.2147\/CMAR.S201975","article-title":"Human papillomavirus DNA in surgical smoke during cervical loop electrosurgical excision procedures and its impact on the surgeon","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jmii.2025.03.009_bib124","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/oemed-2019-106333","article-title":"Human papillomavirus and surgical smoke: a systematic review","volume":"77","author":"Fox-Lewis","year":"2020","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.jmii.2025.03.009_bib125","year":"2020"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:51:29Z","timestamp":1762555889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1684118225000714"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.03.009","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations and guidance for human papillomavirus (HPV) vaccination for adults in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}